| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| mm-121 | erbb3 tyrosine kinase receptor | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant neoplasm of breast[MeSHID:D001943] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
8.49 | phase 2 | unknown |
| mm-121 | erbb3 tyrosine kinase receptor | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant neoplasm of breast[MeSHID:D001943] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
8.49 | phase 2 | antibody |
| mm-121 | erbb3 tyrosine kinase receptor | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant neoplasm of breast[MeSHID:D001943] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
8.49 | phase 2 | antagonist |
| click here to return to the previous page | ||||||||